White paperThe Enterprise Framework for Compliant, Scalable AI
Download now
Continuous complianceDataRegulations

Complaints Remediation to Meet FDA Consent Decree Deadline

Case study on Complaints Remediation to Meet FDA Consent Decree Deadline.

Client profile: Global medical device company operating under an FDA Consent Decree, with a backlog of more than 600,000 service orders and complaints.

Complaints Remediation to Meet FDA Consent Decree Deadline graphic

Executive takeaway

A global medical device company cleared a backlog of over 600,000 service orders and met its FDA Consent Decree deadlines, then kept a sustainable, GxP-aligned complaint handling process in place for the long term.

Service Orders Remediated

600,000+

Complaints backlog of service orders processed, coded, and closed out to satisfy the Consent Decree.

Dedicated Consultants

36

USDM consultants plus USDM leadership stood up a sustainable process the customer's internal staff could not support alone.

Consent Decree Outcome

Deadlines met

Customer achieved FDA Consent Decree deadlines and remediation, and now runs a more efficient complaint handling process.

Before USDM

  • Operating under an FDA Consent Decree with a backlog of more than 600,000 service orders and complaints
  • Internal staff could not keep up with service orders or support the Consent Decree timeline
  • No sustainable, repeatable process to process, code, and close out complaints quickly

After USDM

  • FDA Consent Decree deadlines and remediation achieved
  • Backlog of 600,000+ service orders processed and closed out by a 36-person USDM team with USDM leadership
  • A sustainable, GxP-aligned complaint handling process that reduces time to process and close out complaints

Overview

Learn how USDM enabled a global medical device company to address an FDA Consent Decree and close out a complaints backlog of over 600,000 service orders. A sustainable process was developed to help the customer reduce the time it takes to process, code, and close out complaints.

The Challenge

A global medical device company was operating under an FDA Consent Decree and struggling to keep up with the volume of service orders and complaints flowing into its quality system. The scope of the problem was significant: more than 600,000 service orders needed to be processed, coded, and closed out.

  • The customer struggled to keep up with incoming service orders and complaints.
  • The customer needed to close out complaints faster to satisfy regulators.
  • Internal staff could not support the Consent Decree timeline.
  • The backlog included more than 600,000 service orders awaiting remediation.

Missing a Consent Decree deadline carries real consequences, and complaint records are a core data integrity obligation. The customer needed both speed and a process that would hold up to regulatory scrutiny.

The Approach

USDM provided a team of 36 consultants, backed by USDM leadership, to develop and run a sustainable process for handling service orders and complaints. Rather than simply adding hands, the team built a repeatable workflow the customer could continue to operate after remediation.

  • Stood up a 36-person team with USDM leadership to design a sustainable, repeatable complaint handling process.
  • Applied USDM domain expertise to quickly address the backlog of 600,000 service orders.
  • Reduced the time required to process, code, and close out complaints.

The work was grounded in GxP best practices and the kind of 21 CFR Part 11 record discipline FDA expects from a complaint handling system, so every closure stood up to audit. Embedding the process within a continuous compliance approach meant the customer would stay in control long after the deadline passed.

The Results

The remediation effort delivered on the regulatory deadline and left the customer better positioned for the future.

  • Customer achieved FDA Consent Decree deadlines and remediation.
  • Backlog of 600,000+ service orders processed and closed out.
  • Customer now uses GxP best practices to manage complaints.
  • Customer now has a more efficient complaint handling process.

By pairing experienced people with a sustainable, GxP-aligned process, the customer cleared its backlog, met its Consent Decree obligations, and walked away with a complaint handling capability it can run on its own. To learn more, download the Complaint and CAPA Management solution overview, or contact USDM to discuss your own remediation timeline.

Continuous Compliance

Facing a Consent Decree or complaints backlog?

USDM stands up the people, GxP processes, and quality discipline needed to clear complaint backlogs and meet FDA remediation deadlines—then keeps you compliant for the long term. Let's talk about your timeline.

Talk to a Compliance Expert

Go deeper

Related guidance

Blogs, webinars, and white papers on the capabilities behind this outcome.

White Paper

Applications of Blockchain Technology Within Pharmaceutical Supply Chain and Quality Management Systems

A practical white paper on applying blockchain to pharmaceutical supply chains and QMS — strengthening traceability, chain of custody, data integrity, and anti-counterfeit controls in regulated life sciences.

Read
Webinar

NetSuite for GxP, Regulated Use Cases

Watch this on-demand webinar to see how life sciences organizations use NetSuite for GxP-regulated processes — from item and material management to 21 CFR Part 11 e-records, audit trails, and e-signatures — and how USDM reduces the compliance burden.

Read
Webinar

Work Faster and Smarter in Biotech Quality Management

Watch this on-demand webinar to see how Box, ComplianceQuest, and USDM Life Sciences bundle quality management so biotechs cut stand-up times, control costs, and run a best-of-breed compliance stack.

Read
Blog

Another Regional UDI Database: Singapore's UDI Implementation

Singapore's HSA UDI system aligns to IMDRF principles but diverges from U.S. rules on convenience kits and software UDIs. Here's what device makers must submit to the SMDR and Class A database, and how to manage the data.

Read
Webinar

EUDAMED Has Landed – What It Means for You, Now

Watch this on-demand session with Jay Crowley on the EUDAMED mandatory-use milestone: what the first four modules activate, why May 28, 2026 matters, and how to turn MDR/IVDR and UDI data readiness into a practical plan.

Read
Webinar

Mandatory Use of EUDAMED Now Starting Q1 2026

Watch this on-demand webinar from USDM Life Sciences and BAYARD to understand the EU's gradual EUDAMED roll-out, why mandatory UDI and device registration now starts in Q1 2026, and how to manage your UDI data to meet the deadline.

Read

Start here

Put AI to work in life sciences — with the right guardrails underneath.

Start with a structured AI Readiness Assessment: fixed-fee, executive-ready, and built to surface the highest-value workflows first.

Start here

Talk to USDM

Tell us what workflow or outcome you want to improve and we'll map the right AI, governance, and delivery path.

By submitting this form, you agree to USDM’s Privacy Policy and consent to receive communications from USDM. You can unsubscribe at any time using the link in our emails.